


IRON

Metabolism

From Molecular Mechanisms
to Clinical Consequences

Fourth Edition

Robert Crichton



WILEY

Iron Metabolism

Iron Metabolism – From Molecular Mechanisms to Clinical Consequences

Fourth Edition

ROBERT CRICHTON

Université Catholique de Louvain, Belgium

WILEY

This edition first published 2016
© 2016 John Wiley & Sons, Ltd.

Registered Office

John Wiley & Sons, Ltd. The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, United Kingdom

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com.

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for every situation. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication data applied for

ISBN 9781118925614

A catalogue record for this book is available from the British Library.

Set in 10/12pt Times by SPi Global, Pondicherry, India

Cover image: Protein Structure of hepcidin courtesy of Brad Jordan, Discovery Attribute Sciences, Amgen, Inc., Thousand Oaks, CA, USA (*J. Biol. Chem.*, **284**, 24155–24167 (2009); <http://dx.doi.org/10.1074/jbc.M109.017764>.)
Schematic of regulation of hepatic hepcidin production courtesy of Dr Andrea Steinbicker, Universitätsklinikum Münster, Germany (*Nutrients*, **5** (8), 3034–3061 (2013); doi: 10.3390/nu5083034.)

Contents

<i>Preface</i>	xii
1 Solution Chemistry of Iron	1
1.1 Iron Chemistry	1
1.2 Interactions of Iron with Dioxygen and Chemistry of Oxygen Free Radicals	2
1.3 Hydrolysis of Iron Salts	5
1.4 Formation and Characterisation of Ferrihydrite	7
1.5 Ageing of Amorphous Ferrihydrite to more Crystalline Products	10
1.6 Biomineralisation	11
1.7 Magnetite Biomineralisation by Magnetotactic Bacteria	13
1.7.1 Biogenesis of the Magnetosome Membrane	15
1.7.2 Protein Sorting	15
1.7.3 Chain Formation	16
1.7.4 Biomineralisation	16
1.7.5 A Model for Magnetosome Formation	17
References	18
2 The Essential Role of Iron in Biology	22
2.1 Introduction: Iron an Essential Element in Biology	22
2.2 Physical Techniques for the Study of Iron in Biological Systems	25
2.3 Classes of Iron Proteins	29
2.4 Haemoproteins	29
2.4.1 Oxygen Carriers	30
2.4.2 Activators of Molecular Oxygen	34
2.4.3 Electron Transport Proteins	38
2.5 Iron–Sulphur Proteins	41
2.6 Non-haem, Non-Fe–S Proteins	48
2.6.1 Mononuclear Non-haem Iron Enzymes	48
2.6.1.1 Extradiol-cleaving Catechol Dioxygenases	49
2.6.1.2 Rieske Oxygenases	49
2.6.1.3 α -Ketoglutarate-dependent Enzymes	52
2.6.1.4 Pterin-dependent Hydroxylases	54
2.6.1.5 Miscellaneous Enzymes	55
2.6.2 Dinuclear Non-haem Iron Proteins	55
2.6.3 Proteins of Iron Storage, Transport and Metabolism	61
2.7 The Dark Side of Iron: ROS, RNS and NTBI	62
2.7.1 ROS and RNS	63
2.7.2 NTBI and LPI	64
References	64

3	Microbial Iron Uptake	71
3.1	Introduction	71
3.2	Iron Uptake from Siderophores	74
3.2.1	Siderophores	74
3.2.2	Iron Transport across the Outer Membrane in Gram-negative Bacteria	78
3.2.3	Transport across the Periplasm and Cytoplasmic Membrane in Gram-negative Bacteria	86
3.2.4	Iron Uptake by Gram-positive Bacteria	92
3.3	Fe ²⁺ Transport Systems	93
3.4	Iron Release from Siderophores in the Cytoplasm	97
3.5	Intracellular Iron Metabolism	98
3.6	Control of Gene Expression by Iron	101
	References	108
4	Iron Acquisition by Pathogens	120
4.1	Introduction	120
4.2	Host Defence Mechanisms, Nutritional Immunity	121
4.3	Pathogenicity and PAIs	123
4.4	Pathogen-specific Iron Uptake Systems	125
4.4.1	Siderophores Associated with Virulence	125
4.4.2	Transferrin/lactoferrin Iron Uptake	126
4.4.3	Haem Iron Uptake	133
4.4.4	Ferrous Iron Uptake	138
4.4.5	Ferric Citrate Uptake by <i>Bacillus cereus</i>	141
4.5	Role of Fur and Fur Homologues in Virulence	141
4.6	Role of Pathogen ECF Sigma Factors	141
4.7	Fungal Pathogens	143
	References	146
5	Iron Uptake by Plants and Fungi	155
5.1	Iron Uptake by Plants	155
5.1.1	Introduction	155
5.1.2	Genome Sequencing	157
5.1.2.1	Quantitative Trait Loci	158
5.1.3	Iron Acquisition by the Roots of Plants	160
5.1.3.1	Non-graminaceous Plants	161
5.1.3.2	Graminaceous Plants	164
5.1.4	Long-distance Iron Transport	166
5.2	Iron Metabolism and Homeostasis in Plants	169
5.2.1	New Tools in Plant Research	169
5.2.2	Intracellular Iron Metabolism	170
5.2.3	Plant Iron Homeostasis	171
5.2.4	Diurnal Regulation of Iron Homeostasis	176
5.3	Iron Uptake, Metabolism and Homeostasis in Fungi	178
5.3.1	Introduction	178
5.3.2	High- and Low-affinity Iron Uptake Pathways	179
5.3.3	Siderophore-mediated Iron Uptake	184

5.3.4	Intracellular Iron Metabolism	185
5.3.5	Iron Homeostasis	186
	References	190
6	Cellular Iron Uptake and Export in Mammals	205
6.1	The Transferrins	205
6.1.1	Introduction	205
6.1.2	The Transferrin Family	206
6.1.3	Structure of Transferrins	211
6.1.4	Transferrin Iron Binding	215
6.1.5	Binding of other Metals by Transferrin	218
6.2	Cellular Iron Uptake	219
6.2.1	The Transferrin Receptors	219
6.2.2	The Transferrin to Cell Cycle and Iron Release	222
6.2.3	Iron Uptake from other Sources	228
6.3	Cellular Iron Export	230
	References	236
7	Mammalian Iron Metabolism and Dietary Iron Absorption	247
7.1	An Overview of Mammalian Iron Metabolism	247
7.1.1	Introduction	247
7.1.2	The Way Different Cells Handle Iron	249
7.2	Mammalian Iron Absorption	251
7.2.1	Introduction	251
7.2.2	The Intestinal Mucosa	252
7.2.3	Sources of Dietary Iron	253
7.2.4	Iron Loss and Effects on Uptake	255
7.3	Molecular Mechanisms of Mucosal Iron Absorption	256
7.3.1	Iron Uptake at the Apical Pole	256
7.3.2	Iron Transit Through and Storage in Enterocytes	259
7.3.3	Iron Efflux across the Basolateral Membrane	259
7.3.4	Regulation of Iron Uptake by the Enterocyte	261
	References	261
8	Intracellular Iron Utilisation	265
8.1	Intracellular Iron Pools	265
8.1.1	Introduction	265
8.1.2	The Cytosolic Labile Iron Pool (LIP)	266
8.1.3	Distribution of Iron in the Cytosol	268
8.1.4	Other Intracellular Iron Pools	269
8.2	Mitochondrial Iron Metabolism	271
8.2.1	Mitochondrial Iron Uptake and Storage	271
8.2.2	Mitochondrial Fe–S Protein Biogenesis	271
8.2.3	Maturation of Cytosolic and Nuclear Fe–S Proteins	275
8.2.4	Haem Biosynthesis	283
8.3	Haem Oxygenase	287
8.3.1	Structure and Catalytic Cycle	287
8.3.2	Activation of Haem Oxygenase 1 (HO-1)	292
	References	292

9	Iron Storage Proteins	300
9.1	Introduction	300
9.2	The Ferritin Superfamily and Haemosiderins	301
9.2.1	The Ferritin Superfamily	301
9.2.2	Structure of Vertebrate and Invertebrate Ferritins	304
9.2.3	Plant and Bacterial Ferritins	308
9.2.4	Dps Proteins and Rubrerythrins	313
9.2.5	The Mineral Core	319
9.2.6	Haemosiderins	319
9.3	Iron Uptake and Release from Ferritin	320
9.3.1	Iron Uptake in Ferritins	320
9.3.1.1	Entry of Fe(II) into the Protein Shell	321
9.3.1.2	Oxidation of Fe ²⁺ by Ferroxidase Sites	323
9.3.1.3	Mineralisation of the Iron Core	325
9.3.2	Iron Uptake in Dps Proteins	333
9.3.3	Iron Release from Ferritin	333
9.4	Biotechnological Applications of Ferritins	335
	References	336
10	Cellular and Systemic Iron Homeostasis	346
10.1	Cellular Iron Homeostasis	346
10.1.1	Translational Control of Protein Synthesis	346
10.1.2	The IRE/IRP System	347
10.1.3	The IREs – Distribution and Structure	348
10.1.4	Structural Features of IRP1 and 2	351
10.1.5	The IRE/IRP System Revisited – Iron Controls Iron	353
10.1.6	Metabolic Consequences of Mutations in IREs	357
10.2	Systemic Iron Homeostasis	357
10.2.1	Introduction	357
10.2.2	Hepcidin, the Key Player	358
10.2.3	Factors which Regulate Hepcidin Synthesis	360
10.2.3.1	Iron Availability	361
10.2.3.2	Inflammatory Stimuli	364
10.2.3.3	Erythropoietic Demand	364
10.2.3.4	Hypoxia	365
10.2.3.5	Endocrine Signals	366
10.3	Integration of Iron Homeostatic Systems	367
	References	367
11	Iron Deficiency, Iron Overload and Therapy	376
11.1	Iron-deficiency Anaemia (IDA)	376
11.1.1	Introduction – The Size of the Problem	376
11.1.2	Causes of IDA	378
11.1.3	Clinical Stages and Diagnosis of IDA	380
11.1.4	Therapeutic Approaches	383
11.1.5	Anaemia of Chronic Disease (ACD), Iron Refractory IDA (IRIDA) and Anaemia of Chronic Kidney Disease (CKD)	384

11.2	Hereditary Iron Overload	386
11.2.1	Introduction	386
11.2.2	Hereditary Haemochromatosis (HH)	386
11.2.3	Causes of HH	387
11.2.4	Types of Haemochromatosis	388
11.2.4.1	HFE-related (Type 1) Haemochromatosis	388
11.2.4.2	Juvenile (Type 2) Haemochromatosis	390
11.2.4.3	TfR2-related (Type 3) Haemochromatosis	390
11.2.4.4	Ferroportin Disease	390
11.2.5	Therapy of Hereditary Haemochromatosis	391
11.3	Acquired Iron Overload	395
11.3.1	Introduction – Causes of Acquired Iron Overload	395
11.3.2	Mechanisms of Iron Toxicity	397
11.3.3	Evaluation of Iron Overload	398
11.3.4	Chelation Therapy for Acquired Iron Overload	400
11.3.5	Other Therapeutic Approaches	405
	References	406
12	Iron and Immunity	418
12.1	Introduction	418
12.1.1	Innate Immunity	419
12.2	The Key Role of Macrophages	422
12.2.1	Overview	422
12.2.2	Macrophage Phenotypes	425
12.2.3	Microglia	426
12.3	Effect of Iron Status on Phagocytic Cell Function	429
12.3.1	Iron Deficiency	429
12.3.2	Iron Overload	430
12.4	Effect of Phagocytic Cell Function on Iron Metabolism	431
12.4.1	The IRE–Iron Regulatory Protein (IRP) System	431
12.5	Effector Molecules of the Innate Immune System	433
12.5.1	Toll-like Receptors	433
12.5.2	NF- κ B	433
12.5.3	Hypoxia-Inducible Factor 1 (HIF 1)	434
12.5.4	Haem Oxygenase	435
12.5.5	DMT1, Nramp1	437
12.6	Adaptive Immunity	437
12.6.1	CD8 ⁺ Lymphocytes and Cytotoxicity	438
12.6.2	CD4 ⁺ Lymphocytes	438
12.7	Immune Function and other Factors	438
12.7.1	Iron Supplementation and Immune Function	438
12.7.2	Immune Function in the Elderly Population	439
12.7.3	Iron Overload and Immune Function	439
12.7.4	Thalassaemia	440
12.8	Concluding Remarks	440
	References	440

13	Iron and Oxidative Stress	444
13.1	Oxidative Stress	444
13.1.1	Introduction – Milestones in the History of Life	444
13.1.2	Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS)	447
13.1.3	Cellular Defence Mechanisms Against Oxidative Stress	450
13.1.4	Role of ROS and RNS in Cell Signalling	460
13.1.5	ROS, RNS and Oxidative Damage	466
	References	476
14	Interactions between Iron and other Metals	482
14.1	Introduction	482
14.2	Iron Interactions with Essential Metals	483
14.2.1	Copper	483
14.2.1.1	Introduction	483
14.2.1.2	Copper Acquisition and Metabolism	485
14.2.1.3	Copper Chaperones	486
14.2.1.4	Iron–Copper Interactions	487
14.2.2	Zinc	494
14.2.2.1	Introduction	494
14.2.2.2	Iron–Zinc Interactions	496
14.2.3	Cobalt	497
14.2.3.1	Introduction	497
14.2.3.2	Iron–Cobalt Interactions	498
14.2.4	Manganese	500
14.2.4.1	Iron–Manganese Interactions	500
14.2.5	Calcium	501
14.2.5.1	Iron–Calcium Interactions	501
14.3	Iron Interactions with Toxic Metals	502
14.3.1	Lead	502
14.3.2	Cadmium	503
14.3.3	Aluminium	505
	References	507
15	Iron Homeostasis and Neurodegeneration	516
15.1	Introduction	516
15.2	Brain Iron	517
15.2.1	Brain Iron Homeostasis	517
15.2.2	Aging and Brain Iron Content	518
15.3	Iron and Neurodegeneration	522
15.3.1	Introduction	522
15.3.2	Adverse Effects of Iron in Neurodegeneration	522
15.3.2.1	Toxicity of ROS and RNS	522
15.3.2.2	Iron and Mitochondrial Function	523
15.3.2.3	Protein Aggregation	523
15.4	Neurodegeneration with Brain Iron Accumulation	524
15.4.1	Aceruloplasminaemia	524
15.4.2	Neuroferritinopathy	526
15.4.3	Other NBIA's	528

15.5 Other Monogenic Neurodegenerative Diseases	530
15.5.1 Huntington's Disease	530
15.5.2 Friedreich's Ataxia	532
15.6 Neurodegeneration Involving Multiple Genes	533
15.6.1 Parkinson's Disease (PD)	533
15.6.2 Alzheimer's Disease (AD)	535
15.6.3 Multiple Sclerosis (MS)	537
15.7 Intracerebral Haemorrhage	538
References	539
<i>Concluding Remarks</i>	544
<i>Index</i>	547

Preface

It is astonishing to realise that a slim volume of some 260 pages (Crichton, 1991), first conceived in the course of a discussion with the egregious Ellis Horwood at the Christmas buffet of the Royal Society of Chemistry Inorganic Biochemistry Discussion Group, has grown to such a size. Ellis Horwood had established his own scientific publishing house, Ellis Horwood Limited, based in the charming old Market Cross House in the West Sussex town of Chichester and, with his usual inimitable enthusiasm, he persuaded me – rather easily as it turned out – to contribute to his series of *Inorganic Chemistry* books. The outcome was *Inorganic Biochemistry of Iron Metabolism*, and any thoughts of subsequent editions had certainly not crossed my mind.

I say rather easily, because since the publication of the proceedings of the second meeting on proteins of iron storage and transport (Crichton, 1975), there had been a void which was crying out to be filled for a definitive work which would bring together an overview of the dramatic developments which had been taking place in the field of iron metabolism since then. All of the manuscripts of the presentations at that meeting in Louvain-la-Neuve were incorporated into the book *Proteins of Iron Storage and Transport in Biochemistry and Medicine*, produced by North Holland/American Elsevier in record time – the meeting was held from 2nd–5th April, 1975 and the book (all 454 pages) appeared in July of that year! They included the contribution by Jean Montreuil and Genevieve Spik from Lille, who arrived without a manuscript, but after being closeted in an office with an English-speaking secretary, duly produced the goods before the end of the meeting, as well as Clem Finch's Concluding Remarks recorded on a Dictaphone at the end of the meeting, typed that evening during the concluding Banquet, and duly dispatched, corrected, the following morning along with all of the other camera-ready texts. This volume, which represented the first time that all of the major figures on the iron scene had published jointly what was a sort of 'state of the art of iron metabolism, 1975', sold over 600 copies, and was still being cited more than a decade after the meeting itself. However, despite intermittent efforts after the New York meeting in 1977, the Sapporo meeting in 1983 and the Lille meeting in 1985 (Brown *et al.*, 1977; Uroshizaki *et al.*, 1983; Spik *et al.*, 1985), there was a real potential for a book that would bring together all aspects of iron metabolism.

My decision to undertake this ambitious project was greatly facilitated by the fact that I was in line for a sabbatical – in reality six rather than 12 months – which I spent at the invitation of Professor Robert Freedman in the Biology Department of the University of Kent in Canterbury. Ironically (no pun intended) for the author of a book on inorganic chemistry, my office was in the Chemistry Department. In those prehistoric times one hunted down references on the shelves of the University library overlooking the majestic and historical Cathedral, photocopied them (a new innovation), and then read them, highlighting the important sections. When the references (hunted down in *Chemical Abstracts*) were not available in Canterbury, one undertook a day trip to London to consult the Science Library there. Then, with reams of fluorescent highlighted papers, one sat down to write one's own text, mostly in my flat on the Canterbury Road in the agreeable seaside town of Whitstable, with its beach and bracing sea air.

The outcome, in 12 chapters, is quite similar to this 4th edition, dealing with iron chemistry, the importance of iron in biology, microbial, plant and fungal iron uptake, transferrin and its receptor (a relatively recent discovery), intracellular iron, iron homeostasis, iron absorption, iron deficiency and overload, iron and oxidative damage and finally, iron and infection. There were some 800 references in all, regrouped at the end of the book, in the classical chemical presentation without title, but with the final page number. I would think that, with the resources then available, I had read the abstracts of all of the articles (in *Chemical Abstracts*) and read the better part of 50–60% of the most important articles. The figures were entirely in black and white!

When, ten years later, I undertook a 2nd edition (Crichton, 2001), the title – now *Inorganic Biochemistry of Iron Metabolism. From Molecular Mechanisms to Clinical Consequences* – had been transferred to John Wiley & Sons, and the 326-page outcome even had a central glossy page insert which included 16 ‘Plates’ of coloured figures (all of the others were black and white). For this edition I enlisted the help of six colleagues, Volkmar Braun and Klaus Hantke for microbial iron uptake, Jo Marx and Manuela Santos for the pathophysiology of iron deficiency and iron overload, Roberta Ward for the chapter on oxidative stress, and Johann Boelaert for iron and infection. There were some 1500 references, this time regrouped at the end of each chapter, but again without titles. Once again, it is probable (I cannot speak for my colleagues) that at least the abstracts of the papers cited had been read as well as most of the key articles.

By the time of the 3rd edition (Crichton, 2009), I had returned to the essentially single author format, with two chapters being entrusted to my long-term collaborator, Roberta Ward. Reflecting the way the field was growing, the microbial iron chapter included a view of intracellular iron metabolism, while the plant and fungal chapter highlighted the extraordinary developments in our understanding of yeast iron uptake systems. Although discovered just after the 2nd edition, hepcidin was relegated to the iron absorption chapter in which systemic iron balance was reviewed. The chapter on iron and infection was replaced by a new chapter on brain iron homeostasis and its perturbation in neurodegenerative diseases. Virtually all of the figures were in colour, and the 2200 references this time included titles (which makes for a lot more work – as a colleague remarked, “you can always invent the final page number, but the title.....?”, yet I think it is more useful in deciding if the reader really wants to hunt it down).

This 4th edition has reached even larger dimensions, with the number of references soaring to over 3500. As in the previous edition, we begin with a chapter on the solution chemistry of iron in biological media, the biologically very important interactions of iron with dioxygen, followed by a short review of hydrolysis of iron salts, the characterisation of ferrihydrite and its ageing to more crystalline products. The chapter concludes with a section on biomineralisation, with particular emphasis on magnetite formation by magnetotactic bacteria. The essential role of iron in biology is once again reviewed in Chapter 2, illustrated by examples drawn where possible from the recent literature.

The section on microbial iron has been subdivided this time into two chapters to take account of the important role of iron acquisition in the virulence of microbial pathogens and, in particular, as potential antimicrobial therapeutic targets. Chapter 3 discusses iron uptake from ferric siderophores in Gram-negative and Gram-positive bacteria, as well as the systems used by both classes of bacteria to take up Fe^{2+} . Iron release from siderophores and intracellular iron metabolism are then reviewed, and the chapter concludes with a discussion of the mechanisms involved in the regulation of gene expression by iron.

Iron sequestration provides the innate host defence, known as nutritional immunity, which leads bacterial and fungal pathogens to scavenge iron from their hosts. Chapter 4 is devoted to iron assimilation by pathogens, beginning with an overview of host defence mechanisms and

nutritional immunity. The importance of pathogenicity islands, horizontally transferred mobile genetic elements involved in the dissemination of antibiotic resistance and virulence genes in pathogenic organisms, which frequently also encode iron uptake systems, specific to pathogenic strains (Gyles and Boerlin, 2014) is then outlined. Pathogen-specific iron uptake systems, involving pathogen-specific siderophores, host sources of iron such as transferrin, lactoferrin and haem, ferrous iron and ferric citrate, are then analysed. The structural basis of iron piracy by pathogenic *Neisseria* from human transferrin has been elucidated (Noinaj *et al.*, 2012). These studies establish a rational basis for the host specificity of TbpA, the TonB-dependent outer membrane transporter for human transferrin, show how TbpA promotes iron release from transferrin, and elucidate how TbpB, the lipoprotein coreceptor, facilitates this process. Recent cloning and sequencing of transferrin orthologues from 21 hominoid monkey species (Barber and Elde, 2014) revealed that hominoid transferrin has undergone recurrent positive selection at the binding interface with bacterial TbpA, providing a mechanism to counteract bacterial iron piracy. The regulation of pathogen iron uptake by Fur and Fur homologues, and by pathogen ECF sigma factors, are discussed, and we conclude with a brief outline of the strategies employed by opportunistic fungal pathogens, which represent a growing health threat, to acquire iron from their host.

Our understanding of iron uptake by plants and fungi has been greatly influenced by the fulgurant progress in genome sequencing, and Chapter 5 presents our current views on this area, with its important consequences for agriculture. Iron is the most commonly deficient micronutrient in the human diet, with iron deficiency affecting around 1.6 billion people (Chapter 11), and plants represent one of the principal sources of our dietary iron. However, while iron plays a key role among minerals in improving plant product quality, and is an important determinant in photosynthetic efficiency in algae and higher plants (Briat *et al.*, 2015), Fe deficiency – notably in calcareous soils – is very common. As our understanding of iron assimilation and distribution pathways in plants evolves, this information will assist in the development of strategies to improve both iron content and bioavailability of the edible parts of crops, in order to better improve our diet. Chapter 5 begins with a review of iron uptake by plant root systems, together with long distance iron transport in graminaceous and non-graminaceous plants, followed by a review of new tools in plant research, including integrative-omic analyses, and a discussion of intracellular plant iron metabolism and homeostasis. The final part of the chapter gives an account of iron uptake, metabolism and regulation in fungi.

Chapter 6 deals with mammalian cellular iron uptake and export, as in previous editions, beginning with the transferrin superfamily. Most transferrin family members have a familiar bilobal structure, resulting from an ancient gene duplication, with an iron-binding site in each of two homologous lobes. However, in the course of evolution transferrin homologues with a variety of domain architectures are found, including monolobals, bilobals with one or both iron-binding sites abrogated, bilobals with long insertions or with membrane anchors, and even trilobals (Gaffney and Valentine, 2012). Indeed, quite a number of the members do not appear to play any role in iron binding or transport. A discussion of the detailed structure of transferrins is then followed by an analysis of the binding not only of iron, but also of other metal ions, to the transferrin molecule. The structure of the transferrin receptor and its central role in cellular iron uptake from transferrin precedes a summary of other potential sources of cellular iron uptake, and the chapter concludes with an account of ferroportin and its role in iron export.

In Chapter 7 an overview of mammalian iron metabolism is presented, including an account of the diverse ways in which different cells of the body handle iron. The erythrocyte-forming cells of the bone marrow are the main iron *importers*, consuming most of the plasma iron for haem synthesis and its incorporation into the oxygen transport protein haemoglobin. In contrast, both the

enterocytes of the gastrointestinal tract and the macrophages of the spleen and liver (Kupffer cells) are involved in the *import* and *export* of iron. The former capture dietary iron and then export it to the rest of the body. In contrast, splenic macrophages acquire iron from the phagocytosis of effete red blood cells, and then export it through transferrin for the requirements of other cells of the body, with the bulk going to the erythroid bone marrow. Dietary iron absorption from the intestinal mucosa in mammals concludes the Chapter, with an assessment of dietary sources of iron, and a review of the mechanisms of mucosal iron absorption.

Chapter 8 regroups a detailed analysis of our present understanding of intracellular iron utilisation in mammals, opening with a description of intracellular iron pools. Most of the iron taken up by the cell enters the kinetically labile iron pool (LIP) in the cytosol, the functional attributes of which were first presciently described by Allan Jacobs in 1977 (Jacobs, 1977), although its precise nature still seems to be uncertain (Cabantchik, 2014). While most of the iron in the LIP is destined for the mitochondria, there are increasing indications that members of the poly C binding protein (PCBP) family have iron chaperone activity, supplying iron both to ferritin and to enzymes of the family of iron and α -ketoglutarate-dependent dioxygenases (Shi *et al.*, 2008; Nandal *et al.*, 2011). Mitochondrial iron uptake and storage are briefly discussed before a detailed account of the current views on Fe–S cluster biosynthesis, Fe–S protein biogenesis and the maturation of cytosolic and nuclear Fe–S proteins (Stehling *et al.*, 2014). The chapter concludes with a discussion of haem biosynthesis and catabolism, the latter focusing on haem oxygenase and its activation.

Chapter 9 is devoted to iron storage proteins, beginning with a presentation of the ferritin superfamily, made up of at least 12 ‘subfamilies’ (see Figure 9.1), of which the ferritins are the most abundant. Within the superfamily there are three distinct types of iron storing and detoxifying proteins which constitute the ferritin subfamily: the classical 24-meric ferritins; the haem-containing 24-meric bacterioferritins of prokaryotes; and the prokaryotic 12-meric Dps proteins, which bind to and protect DNA. All three are derived from far more simplistic rubrerythrin-like molecules, which play roles in defence against toxic oxygen species (Andrews, 2010). The extensive structural studies on the ferritins, Dps proteins and rubrerythrins are then reviewed, and this first section concludes with an account of the mineral core and the lysosomal degradation product of ferritin, haemosiderin. The second part of the chapter includes a detailed discussion of mechanisms involved in the uptake and release of iron by ferritins and Dps proteins. While there is considerable agreement on how iron enters the protein shell, and on the role of the ferroxidase centre in iron oxidation, there is still some controversy concerning the mechanism of iron storage by ferritins (Honarmand Ebrahimi *et al.*, 2014; Bradley *et al.*, 2014), although the opposing views may end up being reconciled. The chapter concludes with a brief overview of recent biotechnological applications of ferritins.

The exciting recent developments in our understanding of cellular and systemic iron homeostasis and their regulation are outlined in Chapter 10. The role of the IRE/IRP system in the regulation of cellular iron metabolism has undergone much refinement in detail, but the overarching picture of elegance in regulating mRNA translation remains. That is, when iron is scarce the uptake pathways are turned on and the storage and utilisation pathways are turned off, with the reverse happening in iron abundance (Kühn, 2014). Since the serendipitous discovery of its involvement in iron metabolism (Nicolas *et al.*, 2001; Pigeon *et al.*, 2001), the key role of hepcidin in regulating systemic iron homeostasis has become the brightest beacon on the iron scene. As Tom Ganz has elegantly put it, “The iron hormone hepcidin and its receptor and cellular iron exporter ferroportin control the major fluxes of iron into blood plasma: intestinal iron absorption, the delivery of recycled iron from macrophages, and the release of stored iron from hepatocytes” (Ganz, 2013). Finally, over the last few years the role of hypoxia-inducible factors (HIFs), notably HIF-2, in iron homeostasis has emerged. These transcription factors regulate responses to hypoxia but also regulate key proteins of iron

metabolism (Simpson and McKie, 2015). The way in which the activity of hepcidin, the master regulator of systemic iron homeostasis, the cellular IRE/IRP system, and HIF-2 are coordinated will no doubt gradually begin to be better understood. The interplay between the three regulatory systems – the IRE/IRP system, the HIF system and the ultimate key orchestrator of systemic iron homeostasis, the hepcidin/ferroportin system – is slowly beginning to be understood.

Important questions concerning the integration of these regulatory systems remain, some of which are addressed in Chapter 11, which reviews our current understanding of human iron deficiency and iron overload (both hereditary and acquired), together with an assessment of their therapy. The mainstay of iron-deficiency anaemia (IDA) treatment and prevention remains iron fortification of staple foodstuffs, which is considered to be the most cost-effective method for providing additional iron for populations with a high prevalence of IDA (Lynch, 2011). This in turn underlines the importance of developing agronomic, plant breeding and transgenic approaches to increase the Fe content and the bioavailability of the edible parts of crops in order to improve the human diet (Briat *et al.*, 2015). Introduction of the orally active chelator deferasirox (DFX, Exjade®; Novartis Pharma AG, Basel, Switzerland) has allowed a greater diversity of therapeutic strategies for the treatment of acquired iron overload (Saliba *et al.*, 2015). However, as has been pointed out by Ioav Cabantchik (Cabantchik *et al.*, 2013), these chelation regimens might not be suitable for treating disorders of iron maldistribution, as those are characterised by toxic islands of siderosis appearing in a background of normal or subnormal iron levels (e.g. sideroblastic anaemias, neurosiderosis and cardiosiderosis in Friedreich's ataxia and neurosiderosis in Parkinson's disease). New therapeutic approaches involving the normalisation of hepcidin levels in order to lower serum iron levels are being pursued in animal models of haemochromatosis and of acquired iron overload (Ganz, 2013; Schmidt and Fleming, 2014), with particularly promising results in animal models, notably of additive effects when combined with chelation therapy (Schmidt *et al.*, 2015).

Chapter 12 is a new addition, penned by my long-suffering collaborator of many years, Professor Roberta Ward, on the relationship between iron and the body's defence against inflammation and infection, the immune system. Iron and immunity are closely linked. Iron withholding by many of the proteins involved in iron metabolism is a major strategy in preventing bacteria from utilising iron for growth. The monocytes, macrophages, microglia and lymphocytes of the innate immune system are able to combat bacterial insults by carefully controlling their iron fluxes, while a variety of effector molecules, including hypoxia factor-1 and haem oxygenase orchestrate the inflammatory response by mobilising cytokines, neurotrophic factors, chemokines and reactive oxygen species (ROS) and reactive nitrogen species (RNS). Both iron excess or deficiency can adversely affect the ability of these cells to respond to the bacterial insult.

Chapter 13, as in previous editions, examines the dark side of iron's interactions with molecular oxygen. After a brief introduction, the physiological context in which the different ROS and RNS are formed are reviewed, as are the cellular defence mechanisms against ROS and RNS. Particular emphasis is placed on the thioredoxin/peroxiredoxin system (Lu and Holmgren, 2014). We are all familiar with signalling pathways, which involve conformational changes induced by altering the charge of proteins, either by phosphorylation/dephosphorylation via kinases/phosphatases, or by Ca²⁺-binding. However, we have become increasingly aware during the past few decades that, whereas high levels of ROS and RNS have deleterious effects, at low concentrations they can play an important signalling role in the control of cellular function by responding to changes in the intracellular redox potential. The chapter ends with an overview of the role of ROS and RNS in causing oxidative damage, by catalysing pathways which result in essentially irreversible modifications of amino acid residues in proteins.

Since the 2nd edition, a chapter has been devoted to the interactions between iron and other metals, and the 4th edition is no exception. Both experimental data and clinical findings have indicated that diseases of iron metabolism can be associated with alterations in the metabolism of other essential metal ions, particularly divalent cations (Loréal *et al.*, 2014). Chapter 14 first deals with the interactions of iron with the essential metal ions copper, zinc, cobalt, manganese and, for the first time, despite its quite different coordination chemistry, calcium. Exactly how Ca^{2+} interferes with iron transport is not clear, although voltage dependence or intracellular Ca^{2+} signalling seems to be ruled out (Shawki and MacKenzie, 2010). There are many toxic ‘heavy’ metals, some of which have gained access to the human population as a result of our own activities, such as the leaching of aluminium, the most abundant metal in the Earth’s crust, into our environment as a consequence of the acid rain generated by emissions of sulphur dioxide and nitrogen oxide; in some regions of Eastern Europe the soil pH values fell below 3. We discuss the interference of the nonessential, toxic metals lead, cadmium and aluminium with iron.

The final chapter, also written in collaboration with Roberta Ward, addresses a subject which has been of particular interest to both of us over the past decade (Crichton and Ward, 2006, 2014; Ward *et al.*, 2013), namely the role of iron in neurodegenerative diseases. When we first advanced the idea that many neurodegenerative diseases involved dysfunction of brain homeostasis of essential metal ions – notably iron, copper and zinc (Crichton and Ward, 2006) – the evidence was not nearly as convincing as it is today. Sadly, our understanding of brain iron homeostasis is still in its infancy, but neurodegeneration with brain iron accumulation now covers – as the reader can see in Chapter 15 – a wide range of neurodegenerative diseases, including Parkinson’s, Alzheimer’s and Huntington’s diseases and multiple sclerosis.

So, there have been many developments in iron metabolism since the last edition, and I assume the entire responsibility for any omissions or errors that have undoubtedly crept into my text, if only on account of the length and breadth of its subject matter. I would also like to thank Roberta Ward for her important contributions to Chapters 12 and 15, and to the many colleagues, who have given me useful advice.

Robert Crichton
January, 2016

References

- Andrews, S.C. (2010) The Ferritin-like superfamily: Evolution of the biological iron storeman from a rubrerythrin-like ancestor. *Biochim. Biophys. Acta*, **1800**, 691–705.
- Barber, M.F. and Elde, N.C. (2014) Nutritional immunity. Escape from bacterial iron piracy through rapid evolution of transferrin. *Science*, **346**, 1362–1366.
- Bradley, J.M., Moore, G.R. and Le Brun, N.E. (2014) Mechanisms of iron mineralization in ferritins: one size does not fit all. *J. Biol. Inorg. Chem.*, **19**, 775–785.
- Briat, J.F., Dubos, C. and Gaymard, F. (2015) Iron nutrition, biomass production, and plant product quality. *Trends Plant Sci.*, **20**, 33–40.
- Brown, E.B., Aisen, P., Fielding, J. and Crichton, R.R. (1977) *Proteins of Iron Metabolism*. Grune & Stratton, New York, 443 pp.
- Cabantchik, Z.I. (2014) Labile iron in cells and body fluids: physiology, pathology, and pharmacology. *Front. Pharmacol.*, **5**, 45.
- Cabantchik, Z.I., Munnich, A., Youdim, M.B. and Devos, D. (2013) Regional siderosis: a new challenge for iron chelation therapy. *Front. Pharmacol.*, **4**, 167.
- Crichton, R.R. (ed.) (1975) *Proteins of Iron Storage and Transport in Biochemistry and Medicine*. North-Holland/American Elsevier, Amsterdam, New York, 454 pp.
- Crichton, R.R. (1991) *Inorganic Biochemistry of Iron Metabolism*. Ellis Horwood, Chichester, 263 pp.

- Crichton, R.R. (2001) *Inorganic Biochemistry of Iron Metabolism: From Molecular Mechanisms to Clinical Consequences*, 2nd edn. John Wiley & Sons Ltd, Chichester, 326 pp.
- Crichton, R.R. (2009) *Inorganic Biochemistry of Iron Metabolism: From Molecular Mechanisms to Clinical Consequences*, 3rd edn. John Wiley & Sons Ltd, Chichester, 461 pp.
- Crichton, R.R. and Ward, R.J. (2006) *Metal-based Neurodegeneration: From Molecular Mechanisms to Therapeutic Strategies*. John Wiley & Sons Ltd, Chichester, 227 pp.
- Crichton, R.R. and Ward, R.J. (2014) *Metal-based Neurodegeneration*. John Wiley & Sons Ltd, Chichester, 423 pp.
- Gaffney, J.P. and Valentine, A.M. (2012) Beyond bilobal: transferrin homologs having unusual domain architectures. *Biochim. Biophys. Acta*, **1820**, 212–217.
- Ganz, T. (2013) Systemic iron homeostasis. *Physiol. Rev.*, **93**, 1721–1741.
- Gyles, C. and Boerlin, P. (2014) Horizontally transferred genetic elements and their role in pathogenesis of bacterial disease. *Vet. Pathol.*, **51**, 328–340.
- Honarmand Ebrahimi, K.H., Hagedoorn, P.L. and Hagen, W.R. (2014) Unity in the biochemistry of the iron-storage proteins ferritin and bacterioferritin. *Chem. Rev.*, **115**, 295–326.
- Jacobs, A. (1977) Low molecular weight intracellular iron transport compounds. *Blood*, **50**, 433–439.
- Kühn, L.C. (2014) Iron regulatory proteins and their role in controlling iron metabolism. *Metallomics*, **7**, 232–243.
- Loréal, O., Cavey, T., Bardou-Jacquet, E., *et al.* (2014) Iron, hepcidin and the metal connection. *Front. Pharmacol.*, **5**, 128.
- Lu, J. and Holmgren, A. (2014) The thioredoxin antioxidant system. *Free Radic. Biol. Med.*, **66**, 75–87.
- Lynch, S.R. (2011) Why nutritional iron deficiency persists as a worldwide problem. *J. Nutr.*, **141**, 763S–768S.
- Nandal, A., Ruiz, J.C., Subramanian, P., *et al.* (2011) Activation of the HIF prolyl hydroxylase by the iron chaperones PCBPI and PCBP2. *Cell Metab.*, **14**, 647–657.
- Nicolas, G., Bennoun, M., Devaux, I., *et al.* (2001) Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. *Proc. Natl Acad. Sci. USA*, **98**, 8780–8785.
- Noinaj, N., Easley, N.C., Oke, M., *et al.* (2012) Structural basis for iron piracy by pathogenic *Neisseria*. *Nature*, **483**, 53–58.
- Pigeon, C., Ilyin, G., Courselaud, B., *et al.* (2001) A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. *J. Biol. Chem.*, **276**, 7811–7819.
- Saliba, A.N., Harb, A.R. and Taher, A.T. (2015) Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. *J. Blood Med.*, **6**, 197–209.
- Schmidt, P.J. and Fleming, M.D. (2014) Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches. *Hematol. Oncol. Clin. North Am.*, **28**, 387–401.
- Schmidt, P.J., Racie, T., Westerman, M., *et al.* (2015) Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β -thalassemia intermedia. *Am. J. Hematol.*, **90**, 310–313.
- Shawki, A. and Mackenzie, B. (2010) Interaction of calcium with the human divalent metal-ion transporter-1. *Biochem. Biophys. Res. Commun.*, **393**, 471–475.
- Shi, H., Bencze, K.Z., Stemmler, T.L. and Philpott, C.C. (2008) A cytosolic iron chaperone that delivers iron to ferritin. *Science*, **320** 1207–1210.
- Simpson, R.J. and McKie, A.T. (2015) Iron and oxygen sensing: a tale of 2 interacting elements? *Metallomics*, **7**, 223–231.
- Spik, G., Montreuil, J., Crichton, R.R. and Mazurier, J. (eds) (1985) *Proteins of Iron Storage and Transport*. Elsevier, Amsterdam, 380 pp.
- Stehling, O., Wilbrecht, C. and Lill, R. (2014) Mitochondrial iron-sulfur protein biogenesis and human disease. *Biochimie*, **100**, 61–77.
- Uroshizaki, I., Aisen, P., Listowsky, I. and Drysdale, J.W. (eds) (1983) *Structure and Function of Iron Storage and Transport Proteins*. Elsevier, Amsterdam, 546 pp.
- Ward, R., Crichton, R. and Dexter, D. (eds) (2013) *Mechanisms and Metal Involvement in Neurodegenerative Diseases*. Royal Society of Chemistry, Metallobiology Series, 226 pp.

1

Solution Chemistry of Iron

1.1 Iron Chemistry

In the Earth's crust, iron is the fourth most abundant element and the second most abundant metal (the most abundant is aluminium). Situated in the Periodic Table in the middle of the first transition series (characterised by having incompletely filled d orbitals), iron has access to a number of oxidation states (from -II to +VI), the principal being II (d^6) and III (d^5). A number of iron-dependent monooxygenases are able to generate high-valent Fe(IV) or Fe(V) reactive intermediates during their catalytic cycle. Whereas, Fe^{2+} is extremely water-soluble, Fe^{3+} is quite insoluble in water ($K_{\text{sp}} = 10^{-39}$ M and at pH 7.0, $[\text{Fe}^{3+}] = 10^{-18}$ M) and significant concentrations of water-soluble Fe^{3+} species can be attained only by strong complex formation with appropriate ligands.

The interaction between Fe^{2+} and Fe^{3+} and ligand donor atoms will depend on the strength of the chemical bond formed between them. An idea of the strength of such bonds can be found in the concept of 'hard' and 'soft' acids and bases (HSAB) (Pearson, 1963). 'Soft' bases have donor atoms of high polarisability with empty, low-energy orbitals; they usually have low electronegativity and are easily oxidised. In contrast, 'hard' bases have donor atoms of low polarisability, and only have vacant orbitals of high energy; they have high electronegativity and are difficult to oxidise. Metal ions are 'soft' acids if they are of low charge density, have a large ionic radius, and have easily excited outer electrons. 'Hard' acid metal ions have high charge density, a small ionic radius, and no easily excited outer electrons. In general, 'hard' acids prefer 'hard' bases and 'soft' acids form more stable complexes with 'soft' bases (Pearson, 1963). Fe(III) with an ionic radius of 0.067 nm and a charge of $3+$ is a 'hard' acid and will prefer 'hard' oxygen ligands such as phenolate and carboxylate, compared to imidazole or thiolate. In contrast, Fe(II) with an ionic radius of

0.083 nm and a charge of only 2^+ is on the borderline between ‘hard’ and ‘soft,’ favouring nitrogen (imidazole and pyrrole) and sulphur ligands (thiolate and methionine) over oxygen ligands.

The coordination number of 6 is the most frequently found for both Fe(II) and Fe(III) giving octahedral stereochemistry, although four-coordinate (tetrahedral) and particularly five-coordinate complexes (trigonal bipyramidal or square pyramidal) are also found. For octahedral complexes, two different spin states¹ can be observed. Strong-field ligands (e.g. $\text{Fe}^{3+} \text{OH}^-$), where the crystal field splitting is high and hence electrons are paired, give low-spin complexes, while weak-field ligands (e.g. CO, CN^-), where crystal field splitting is low, favour a maximum number of unpaired electrons and give high-spin complexes. Changes of spin state affect the ion size of both Fe(II) and Fe(III), the high-spin ion being significantly larger than the low-spin ion. As we will see in Chapter 2, this is put to good use as a trigger for the cooperative binding of dioxygen to haemoglobin. High-spin complexes are kinetically labile, while low-spin complexes are exchange-inert. For both oxidation states only high-spin tetrahedral complexes are formed, and both oxidation states are Lewis acids, particularly the ferric state.

The unique biological role of iron comes from the extreme variability of the $\text{Fe}^{2+}/\text{Fe}^{3+}$ redox potential, which can be fine-tuned by well-chosen ligands, so that iron sites can encompass almost the entire biologically significant range of redox potentials, from about -0.5 V to about $+0.6$ V. However, as we will see in Chapter 13, copper allows access to an even higher range of redox potentials (0 V to $+0.8$ V), which turned out to be of crucial importance in the Earth’s rapidly evolving aerobic environment, following the arrival of water-splitting, oxygen-generating photosynthetic organisms.

1.2 Interactions of Iron with Dioxygen and Chemistry of Oxygen Free Radicals

Molecular oxygen was not present when life began on Earth, with its essentially reducing atmosphere, and both the natural abundance of iron and its redox properties predisposed it to play a crucial role in the first stages of life on Earth. About one billion (10^9) years ago, photosynthetic prokaryotes (Cyanobacteria) appeared and dioxygen was evolved into the Earth’s atmosphere. It probably required 200–300 million years – a relatively short time on a geological time scale – for oxygen to attain a significant concentration in the atmosphere, since at the outset the oxygen produced by photosynthesis would have been consumed by the oxidation of ferrous ions in the oceans. Once dioxygen had become a dominant chemical entity, iron hydroxides precipitated, as the Precambrian deposits of red ferric oxides laid down in the geological strata at that time bear witness. Concomitant with the loss of iron bioavailability, the oxidation of Cu(I) led to soluble Cu(II). While enzymes active in anaerobic metabolism were designed to be active in the lower portion of the redox potential spectrum, the presence of dioxygen created the need for a new redox active metal with $E_0^{\text{M}^{n+1}/\text{M}^n}$ from 0 to 0.8 V. Copper, now bioavailable (Crichton and Pierre, 2001), was ideally suited for this role and began to be used in enzymes with higher redox potentials (as a di-copper centre in laccase and a mixed iron-copper centre in cytochrome oxidase) to take advantage of the oxidizing power of dioxygen. Some typical redox potentials for iron and copper proteins and chelates are given in Figure 1.1.

Although oxygen must ultimately completely oxidise all biological matter, its propensity for biological oxidation is considerably slowed by the fact that in its ground state (lowest energy state)

¹ The spin state is defined as the orientation in a strong magnetic field of an unpaired electron (or a nuclear spin), i.e. either parallel or antiparallel to the direction of the magnetic field.




Figure 1.1 Some redox potentials (in Volts) of iron and copper enzymes and chelates at pH 7 relative to the standard hydrogen electrode. Figure reproduced with permission from Crichton and Pierre (2001)

it exists as a triplet spin state, whereas most biological molecules are in the singlet state as their lowest energy level. Spin inversion is relatively slow, so that oxygen reacts much more easily with other triplet state molecules or with free radicals than with singlet state molecules.

The arrangement of electrons in most atoms and molecules is such that they occur in pairs, each of which have opposite intrinsic spin angular momentum. Molecules which have one or more unpaired electrons are termed free-radicals: these are generally very reactive and will act as chain carriers in chemical reactions. Thus, the hydrogen atom, with one unpaired electron, is a free radical, as are most transition metals and the oxygen molecule itself. The dioxygen molecule has two unpaired electrons, each located in a different π^* anti-bonding orbital. Since these two electrons have the same spin quantum number, if the oxygen molecule attempts to oxidise another atom or molecule by accepting a pair of electrons from it, both new electrons must have parallel spins in order to fit into the vacant spaces in the π^* orbitals. A pair of electrons in an atomic or molecular orbital would have anti-parallel spins (of $+\frac{1}{2}$ and $-\frac{1}{2}$) in accordance with Pauli's principle. This imposes a restriction on oxidation by O₂, which means that dioxygen tends to accept its electrons one at a time and slows its reaction with non-radical species (Halliwell and Gutteridge, 1984). Transition metals can overcome this spin restriction on account of their ability to accept and donate single electrons. The interaction of iron centres and oxygen is of paramount importance in biological inorganic chemistry, and some of the main features have been summarised in Figure 1.2.

The reactivity of O₂ can be increased in another way, by moving one of the unpaired electrons in a way that alleviates the spin restriction to give the two singlet states of O₂. The most important of the two forms of singlet O₂¹ δ_g in biological systems has no unpaired electrons, is not a radical,





Figure 1.2 Iron–oxygen chemistry. Multibridged species have been omitted. Figure reproduced with permission from Crichton and Pierre (2001)

and can be obtained when a number of biological pigments such as chlorophylls, retinal, flavins or porphyrins are illuminated in the presence of O_2 . When a single electron is accepted by the ground-state O_2 molecule, it must enter one of the π^* anti-bonding orbitals, to form the superoxide radical, O_2^- . The addition of a second electron to O_2^- gives the peroxide ion O_2^{2-} with no unpaired electrons. At physiological pH, O_2^{2-} will immediately protonate to give hydrogen peroxide, H_2O_2 . The third reactive oxygen species found in biological system is the hydroxyl free radical. Two hydroxyl radicals, $\cdot OH$ can be formed by homolytic fission of the O–O bond in H_2O_2 , either by heating or by irradiation. However, as Fenton first observed in 1894 (Fenton, 1894), a simple mixture of H_2O_2 and an Fe(II) salt also produces the $\cdot OH$ radical (Eq. 1.1):



In the presence of trace amounts of iron, superoxide can then reduce Fe^{3+} to molecular oxygen and Fe^{2+} . The sum of this reaction (Eq. 1.2), plus the Fenton reaction (Eq. 1.1), produces molecular oxygen, hydroxyl radical and hydroxyl anion from superoxide and hydrogen peroxide, in the presence of catalytic amounts of iron – the so-called Haber–Weiss² reaction (Eq. 1.3) (Haber and Weiss, 1934).




Iron or copper complexes will catalyse Fenton chemistry only if two conditions are met simultaneously, namely that the ferric complex can be reduced and that the ferrous complex has an oxidation potential such that it can transfer an electron to H_2O_2 . However, it must also be added that this reasoning supposes that standard conditions are present and at equilibrium, which is rarely the case

² The reaction was originally described by Haber and Wilstätter (1931), but the original paper was published in German! The more frequently cited Haber and Weiss paper does cite the original, but in neither is a reference to Fenton given.

for biological systems. A simple example will illustrate the problem: whereas, under standard conditions reaction (1.2) has a redox potential of -330 mV (at an O_2 concentration of 1 atmosphere), *in vivo* with $[O_2] = 3.5 \times 10^{-5}$ M and $[O_2^-] = 10^{-11}$ M the redox potential is $+230$ mV (Pierre and Fontecave, 1999).

In aqueous solution in the absence of oxygen, iron is present as the hydrated hexa-aqua ferrous II ion, $Fe(H_2O)_6^{2+}$. In the early stages of evolution the atmosphere was thought to be essentially reducing with a very low oxygen pressure, and thus a high concentration of reduced iron would have been present. The appearance of molecular oxygen, which accompanied the arrival of photosynthetic organisms capable of the fixation of atmospheric carbon dioxide with concomitant water splitting to yield electrons, protons and oxygen, changed the situation dramatically, since the following reaction (Eq. 1.4) (here simplified by neglecting the hydration of the ferrous ion) would result:




Except at very low pH values, the hexa-aqua ferric ion, $Fe(H_2O)_6^{3+}$, would then undergo a series of hydrolysis and polymerisation reactions leading progressively to more and more insoluble ferric polynuclears. These would then precipitate to provide geologic evidence of the oxygenation of the atmosphere by the presence around the mid Precambrian of intense red deposits of ferric oxides. The inorganic chemistry involved in these processes is becoming better understood (Jolivet *et al.*, 2004), and the remainder of this chapter is concerned with the pathways of iron hydrolysis and polymerisation, and concludes with some thoughts on biomineralisation.

1.3 Hydrolysis of Iron Salts

Iron salts have a strong predisposition to hydrolyze in aqueous solutions, in a complex process involving the following steps (Flynn, 1984): (i) an initial hydrolysis with the formation of soluble low-molecular-weight complexes; (ii) the formation and ageing of polynuclear clusters; and finally (iii) the precipitation of insoluble Fe(III) oxides and hydroxides. At low pH, iron typically forms hexacoordinated aquo complexes, $[Fe(H_2O)_6]^{z+}$, in which polarisation of the coordinated water molecules will depend on the oxidation state and the size of the cation. Ferric aquo complexes are more acidic than ferrous, and hydroxylation of the cations occurs in very distinct ranges of pH, as can be seen from the speciation diagram (Figure 1.3).

Hydrolysis originates from the loss of protons from the aqua metal ion – going from $[Fe(OH)_h Fe(H_2O)_{6-h}]^{(z-h)+}$, where $h = 0$, with progressively increasing values of h , with each step accompanied by the release of H^+ . The first step for ferric iron is shown in the reaction (Eq. 1.5):



Between pH 5 and pH 9, which is clearly of relevance to living organisms as well as aquatic systems, ferric salts hydrolyze immediately whereas ferrous salts, in the absence of oxygen or other oxidizing agents, give solutions of ferrous aqua ions, $Fe(H_2O)_6^{2+}$. Thus, in biological media the hydrated ferrous ion is a real species (Figure 1.3), whereas the hydrated ferric ion is relatively rare (Jolivet *et al.*, 2004), although significant concentrations of $Fe(H_2O)_6^{3+}$ are present at very low pH values. In most lakes, estuaries, streams and rivers, iron levels are high and Fe^{2+} is produced by the photolysis of inner-sphere complexes of particulate and colloidal iron(III) hydroxides with biogenic organic ligands. Since the photic zones in which this takes place are aerobic, there is continuous






Figure 1.3 Speciation of $[\text{Fe}(\text{OH})_h(\text{H}_2\text{O})_{6-h}]^{(z-h)+}$ complexes of (a) Fe(II); (b) Fe(III). From Jolivet et al. (2004)

reoxidation of iron, producing secondary colloidal iron(III) hydroxides. In deeper waters, settling organic matter can supply reducing equivalents to convert $\text{FeO}\cdot\text{OH}$ to Fe^{2+} . In contrast, iron levels in surface seawater are extremely low, ranging from 0.02 to 1 nM (Wu and Luther, 1996).

Hydroxylated complexes can condense by the elimination of water and formation of μ -hydroxo bridges (olation) (Eq. 1.6), whereas oxohydroxy complexes – where there is no water molecule – condense in a two-step mechanism leading to the formation of μ -oxo bridges (oxolation) (Eq. 1.7):



For ferric complexes, condensation occurs from strongly acidic media (pH ~1), whereas ferrous complexes condense only above pH 6, and the formation of polycationic ferrous species is poorly documented. Ferrous ions under anaerobic conditions can be hydroxylated from the $[\text{Fe}(\text{OH})_2\text{Fe}(\text{H}_2\text{O})_4]^0$ stage at pH > 6–7, leading to the precipitation of $\text{Fe}(\text{OH})_2$. The reaction pathway for the formation of $\text{Fe}(\text{OH})_2$, as shown in Figure 1.4, involves the olation of $[\text{Fe}_2(\text{OH})_2(\text{H}_2\text{O})_8]^{2+}$ dimers to planar tetramers $[\text{Fe}_4(\text{OH})_8(\text{H}_2\text{O})_8]^0$, followed by the rapid growth of nuclei in the same plane and resulting in the layered brucite structure [typical of hydroxides of divalent metal ions – brucite is the mineral form of magnesium hydroxide, $\text{Mg}(\text{OH})_2$]. Both, in the solid state or in aqueous solutions, ferrous phases are extremely sensitive to oxidation, forming mixed ferric–ferrous products (green rusts, magnetite, goethite, lepidocrocite). The rapid oxidation of $\text{Fe}(\text{OH})_2$ at pH 7 represents a unique way to form lepidocrocite, $\gamma\text{-FeO}\cdot\text{OH}$, which is isostructural with the aluminum oxide hydroxide, boehmite, $\gamma\text{-AlO}\cdot\text{OH}$.

The hydrolysis of ferric solutions is readily induced by the addition of base. Upon the addition of base at a rather acid pH, the purple ferric aqua-ion $\text{Fe}(\text{H}_2\text{O})_6^{3+}$ initially undergoes a first




Figure 1.4 A possible reaction pathway for the formation of $\text{Fe}(\text{OH})_2$. From Jolivet *et al.* (2004)

deprotonation step, which is followed by reversible dimerisation, giving a yellow solution of mono- and dinuclear species. The equilibria leading to mono- and dinuclear hydrolysis products such as $[\text{FeOH}]^{2+}$, $[\text{Fe}(\text{OH})_2]^+$ and $[\text{Fe}_2(\text{OH})_2]^{4+}$ are established rapidly and are well understood (Cornell *et al.*, 1989). These low-molecular species interact to produce hydrolytic polymers such as $[\text{Fe}_p(\text{OH})_r(\text{H}_2\text{O})_s]^{(3-r)+}$, or $[\text{Fe}_p\text{O}_r(\text{OH})_s]^{(3p-2r-s)+}$ and precipitated oxides such as $\text{Fe}(\text{OH})_3$, $\text{FeO}\cdot\text{OH}$ and Fe_2O_3 (Feng and Nansheng, 2000; Flynn, 1984; Schwertmann *et al.*, 1999).

On account of their high reactivity, ferric complexes condense very rapidly, and the process is difficult to stop without the use of very strongly complexing polydentate ligands. However, a range of species containing polynuclear Fe(III) cores have been characterised using a number of polycarboxylate or amino ligands (Lippard, 1988; Taft and Lippard, 1990; Taft *et al.*, 1993; Schmitt *et al.*, 2001; Jones *et al.*, 2002; Hellman *et al.*, 2006), two of which are illustrated in Figure 1.5.

1.4 Formation and Characterisation of Ferrihydrite

The addition of base to solutions of ferric ions at pH values >3 immediately leads to the precipitation of a poorly ordered, amorphous, red-brown ferric hydroxide precipitate. This synthetic precipitate resembles ferrihydrite, a hydrous ferric oxyhydroxide mineral found in many near-surface soils and sediments (Rancourt *et al.*, 2001; Schwertmann *et al.*, 1987), and is also present in the iron oxyhydroxide core of the iron storage protein, ferritin (see Chapter 6). Ferrihydrite can be considered as the least stable but most reactive form of iron(III), the group name for amorphous phases with large specific surface areas ($>340\text{ m}^2\text{ g}^{-1}$). The presence of ferrihydrite is often




Figure 1.5 Examples of polycationic structures formed by ferric ions in the presence of strongly complexing ligands. (a) $[\text{Fe}_{19}\text{O}_6(\text{OH})_{14}(\text{L})^{10}(\text{H}_2\text{O})_{12}]^+$ $\text{L} = \text{N}(\text{CH}_2\text{COOH})_2(\text{CH}_2\text{CH}_2\text{OH})$; (b) $\text{Fe}_8(\text{PhCOO})_{12}(\text{thme})_4 \cdot 2\text{Et}_2\text{O}$ (*thme*: tris-hydroxymethylethane). From Jolivet *et al.* (2004)

underestimated because of difficulties in its definitive identification and also because of its common designation (covering a range of poorly ordered compounds), such as amorphous iron hydroxide, colloidal ferric hydroxide, $\text{Fe}(\text{OH})_3$.

Ferrihydrite has been identified as a preterrestrial component of meteorites, and may be a constituent of the soils of Mars (Bishop *et al.*, 1995). On Earth, ferrihydrite is ubiquitous in natural waters, in the sediments derived from these waters, and is a constituent of a wide variety of soils, particularly those formed under cool and moist conditions as the precursor of hematite. It is also abundantly present in the precipitates resulting from acid mine drainage. Its high surface area and reactivity enable it to sequester a number of species through absorption, coprecipitation and redox reactions (Fortin and Langley, 2005). Because of its extremely high surface area and reactivity, ferrihydrite is manufactured for a variety of industrial applications (Li *et al.*, 2011), including coal liquefaction and metallurgical processing (Huffman *et al.*, 1993; Riveros *et al.*, 2001), and as an effective heavy metal scavenger in wastewater treatments (Ford *et al.*, 1997).

The conventional classification of ferrihydrite is based on the number of X-ray diffraction (XRD) peaks. Normally, a distinction is drawn between two types of ferrihydrite, referred to as ‘2-line ferrihydrite,’ which describes a material that exhibits little crystallinity, and ‘6-line ferrihydrite,’ which has the best crystallinity. In a typical XRD pattern of these materials, the 2-line form displays two broad peaks at 1.5 and 2.5 Å, while the more crystalline 6-line form displays six peaks at 1.5 (a doublet), 1.7, 2.0, 2.2, and 2.5 Å (Jambor and Dutrizac, 1998). The degree of order found in synthetic ferrihydrite depends on the method of preparation and the time of its ageing, which requires careful control of pH, temperature and concentration. The brief heating of Fe(III) solutions to about 80 °C typically produces ‘6-line ferrihydrite,’ whereas the 2-line variety is typically produced at ambient temperatures by the addition of alkali to raise the pH to about 7. It seems to be agreed that ferrihydrite is not amorphous and has at least some degree of crystallinity. Despite the ease of its synthesis in the laboratory, no single formula is widely accepted, and compositions ranging from $\text{Fe}_5\text{HO}_8 \cdot 4\text{H}_2\text{O}$ (Towe and Bradley, 1967), through $5\text{Fe}_2\text{O}_3 \cdot 9\text{H}_2\text{O}$ (Towe, 1981) and $\text{Fe}_{10}\text{O}_{14}(\text{OH})_2$ (Michel *et al.*, 2007a) to the recent $\text{Fe}_{8.2}\text{O}_{8.5}(\text{OH})_{7.4} + 3\text{H}_2\text{O}$ (Michel *et al.*, 2010) have been proposed. It has been demonstrated that almost all of the water can be replaced by adsorbed species in quantities that cannot be accommodated within the crystal structure, and it was proposed that the bulk structural unit for ferrihydrite is an $\text{Fe}(\text{O},\text{OH})_6$ octahedron, where the surface




Figure 1.6 Ferrihydrate structure. (a) Unit cell and (b) basic motif of the ferrihydrate model proposed by Michel *et al.*, 2007. From Smith *et al.* (2012)

structure is a mixture of octahedrally and tetrahedrally coordinated Fe (Jambor and Dutrizac, 1998). These ‘coordination-unsaturated’ surface sites are readily accessible to the adsorption of foreign species and, together with the large surface area referred to above, most likely account for the high adsorptive capacity of ferrihydrate.

While it is considered to be a good example of a nanomineral (Hochella *et al.*, 2008), the crystal structure (Jambor and Dutrizac, 1998; Manceau, 2009; Michel *et al.*, 2007a; Rancourt and Meunier, 2008), physical (Rancourt and Meunier, 2008; Hiemstra and Van Rielsdijk, 2009) and magnetic (Coey and Readman, 1973; Pankhurst and Pollard, 1992; Pannalai *et al.*, 2005; Berquo *et al.*, 2007, 2009; Cabello *et al.*, 2009) properties of ferrihydrate remain controversial. Over the years, a number of structural models have been proposed for ferrihydrate (reviewed in Jambor and Dutrizac, 1998). Towe and Bradley (1967) and Chukrov *et al.* (1974) both proposed what were essentially defective hematite structures, whereas Drits *et al.* (1993) proposed a multicomponent model consisting of defective and defect-free ferrihydrate phases mixed with ultradisperse hematite. Unlike other iron hydroxides which have been studied, the exact structure and chemical composition of ferrihydrate has remained a matter of considerable debate, and until recently there has been no consensus on its crystal structure. Most of the disagreement has centred around the presence of multiple structural phases and the local environment of the iron (Drits *et al.*, 1993; Janney *et al.*, 2000, 2001; Jansen *et al.*, 2002).

Recent X-ray scattering studies from both 2-line and 6-line ferrihydrate suggest that the coherent scattering domains share a common structure, despite the fact that the average crystallite size and water content were different (Michel *et al.*, 2007b). An atomic arrangement of ferrihydrate (Figure 1.6) has been proposed (Michel *et al.*, 2007a) using the pair-distribution function (PDF) method for structural analysis, which involves a comparison between PDFs generated from the experimental X-ray scattering data with those calculated from structural models (Billinge and Kanatzidis, 2004). On the basis of their results, these authors concluded that in its ideal form, the structure contains 20% tetrahedrally and 80% octahedrally coordinated iron, and has a basic structural motif closely related to the Baker–Figgis– δ -Keggin cluster³ (Casey, 2006).

³ The Baker–Figgis–Keggin isomers (of which there are five, from α to ϵ) are aluminium hydroxide clusters which have central metals tetrahedrally coordinated to oxygen $[M(O)_4]$ sites, and are familiar structures among scientists who study polyoxometalates. They form aluminium clusters with the stoichiometry $MO_4Al_{12}(OH)_{24}(H_2O)_{12}^{7+}$ (aq) [$M = \text{Ge(IV)}, \text{Ga(III)}, \text{or Al(III)}$].